Shanghai Shyndec Pharmaceutical Co., Ltd. (SHA:600420)
China flag China · Delayed Price · Currency is CNY
8.22
-0.12 (-1.44%)
Sep 24, 2026, 3:00 PM CST

SHA:600420 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
8,2779,21810,77011,78712,81013,756
Other Revenue
148.31145.01167.77282.98149.79189.06
8,4259,36310,93812,07012,95913,945
Revenue Growth
-14.51%-14.39%-9.38%-6.86%-7.07%11.06%
Cost of Revenue
6,0776,4386,8227,5388,0917,909
Gross Profit
2,3482,9254,1164,5324,8686,036
Selling, General & Admin
1,2311,2801,9212,9063,4144,220
Research & Development
375.59437.58565.65562.24517.14584.97
Other Operating Expenses
86.0478.1278.8899113.17128.31
Operating Expenses
1,7011,8122,5633,5494,0274,958
Operating Income
647.061,1141,553983.4841.241,078
Interest Expense
-2.57-4.39-36.89-57.88-107.31-110.47
Interest & Investment Income
169.02177.49151.08136.4861.6948.84
Currency Exchange Gain (Loss)
-32.722.2940.6128.4498.32-32.65
Other Non Operating Income (Expenses)
4.55-2.31-2.01-4.09-4.23-5.75
EBT Excluding Unusual Items
785.341,2871,7051,086889.71978
Impairment of Goodwill
------132.15
Gain (Loss) on Sale of Investments
------24.04
Gain (Loss) on Sale of Assets
-2.59-2.65-31.31-31.85-1.10.2
Asset Writedown
-33.91-32.79-28.26-13.13-4.93-10.81
Other Unusual Items
96.9176.1927.3355.19100.45107
Pretax Income
845.751,3281,6731,097984.12918.21
Income Tax Expense
110.54185.42340.97131.95116.6397.06
Earnings From Continuing Operations
735.211,1421,332964.61867.48821.15
Minority Interest in Earnings
-190.09-200.56-248.46-272.73-239.69-252.87
Net Income
545.12941.61,084691.88627.79568.28
Net Income to Common
545.12941.61,084691.88627.79568.28
Net Income Growth
-47.44%-13.11%56.62%10.21%10.47%-12.41%
Shares Outstanding (Basic)
1,3411,3411,3411,2731,0271,027
Shares Outstanding (Diluted)
1,3411,3411,3411,2731,1561,178
Shares Change
-0.00%-5.31%10.13%-1.82%-0.14%
EPS (Basic)
0.410.700.810.540.610.55
EPS (Diluted)
0.410.700.810.540.540.48
EPS Growth
-47.44%-13.11%48.72%0.07%12.52%-12.29%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
845.191,4342,0361,3632,5481,158
Free Cash Flow Per Share
0.631.071.521.072.200.98
Dividend Per Share
0.2500.3000.3000.1000.1000.100
Dividend Growth
-16.67%0%200.00%0%0%0%
Gross Margin
27.87%31.25%37.63%37.55%37.57%43.28%
Operating Margin
7.68%11.89%14.19%8.15%6.49%7.73%
Profit Margin
6.47%10.06%9.91%5.73%4.84%4.08%
Free Cash Flow Margin
10.03%15.32%18.62%11.29%19.66%8.31%
EBITDA
1,3591,8122,3251,8021,6711,857
EBITDA Margin
16.13%19.36%21.25%14.93%12.90%13.31%
D&A For EBITDA
712.33698.59772.32818.89830.01778.52
EBIT
647.061,1141,553983.4841.241,078
EBIT Margin
7.68%11.89%14.19%8.15%6.49%7.73%
Effective Tax Rate
13.07%13.97%20.38%12.03%11.85%10.57%
Revenue as Reported
8,4259,36310,93812,07012,95913,945
Advertising Expenses
-4.696.184.643.297.1